198 related articles for article (PubMed ID: 32336418)
41. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.
Sapienza MR; Pileri S
Hematol Oncol Clin North Am; 2020 Jun; 34(3):511-521. PubMed ID: 32336416
[TBL] [Abstract][Full Text] [Related]
42. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang Y; Sokol L
Cancer Manag Res; 2022; 14():2107-2117. PubMed ID: 35789956
[TBL] [Abstract][Full Text] [Related]
43. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
Abla D; Abboud MR; Noun D; Tarek N; Pemmaraju N
Leuk Res Rep; 2022; 17():100313. PubMed ID: 35462725
[TBL] [Abstract][Full Text] [Related]
44. Blastic Plasmacytoid Dendritic Cell Neoplasm: The Dermatologist's Perspective.
Hirner JP; O'Malley JT; LeBoeuf NR
Hematol Oncol Clin North Am; 2020 Jun; 34(3):501-509. PubMed ID: 32336415
[TBL] [Abstract][Full Text] [Related]
45. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
Economides MP; McCue D; Lane AA; Pemmaraju N
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
[No Abstract] [Full Text] [Related]
46. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.
Deotare U; Yee KW; Le LW; Porwit A; Tierens A; Musani R; Barth D; Torlakovic E; Schimmer A; Schuh AC; Seftel M; Minden MD; Gupta V; Hyjek E
Am J Hematol; 2016 Mar; 91(3):283-6. PubMed ID: 26619305
[TBL] [Abstract][Full Text] [Related]
47. A Very Rare Type of Leukemia in a Young Pediatric Patient Treated With Hematopoietic Stem Cell Transplantation: Blastic Plasmacytoid Dendritic Cell Neoplasm.
Tekkeşin F; Asarcikli F; Yildirim ÜM; Zemheri IE; Kiliç SÇ
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e288-e291. PubMed ID: 33235146
[TBL] [Abstract][Full Text] [Related]
48. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
[TBL] [Abstract][Full Text] [Related]
49. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
[TBL] [Abstract][Full Text] [Related]
50. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
51. Blastic Plasmacytoid Dendritic Cell Neoplasm in the Pediatric Population: A Case Series and Review of the Literature.
Nguyen CM; Stuart L; Skupsky H; Lee YS; Tsuchiya A; Cassarino DS
Am J Dermatopathol; 2015 Dec; 37(12):924-8. PubMed ID: 26588336
[TBL] [Abstract][Full Text] [Related]
52. [Blastic plasmacytoid dendritic cell neoplasm revealed by ecchymotic lesions on the face].
Ahogo KC; Wantz M; Cliquennois M; Gosset P; Lebas D; Modiano P
Ann Dermatol Venereol; 2014 Jan; 141(1):43-7. PubMed ID: 24461094
[TBL] [Abstract][Full Text] [Related]
53. Treatment of blastic plasmacytoid dendritic cell neoplasm.
Sullivan JM; Rizzieri DA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):16-23. PubMed ID: 27913457
[TBL] [Abstract][Full Text] [Related]
54. Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea.
Kim HS; Kim HJ; Kim SH; Choi JY; Ko YH; Kim WS; Jung CW; Kim SJ
Korean J Intern Med; 2017 Sep; 32(5):890-899. PubMed ID: 28870016
[TBL] [Abstract][Full Text] [Related]
55. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
56. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
57. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.
Pemmaraju N; Konopleva M
Blood Adv; 2020 Aug; 4(16):4020-4027. PubMed ID: 32841341
[TBL] [Abstract][Full Text] [Related]
58. A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy.
Kaur V; Swami A; Shebli A; Shalin S; Veeraputhiran M; Emanuel P; Jethava Y
J Oncol Pharm Pract; 2017 Oct; 23(7):552-556. PubMed ID: 27559020
[TBL] [Abstract][Full Text] [Related]
59. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
Cangini D; Silimbani P; Cafaro A; Giannini MB; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):467-477. PubMed ID: 32955827
[TBL] [Abstract][Full Text] [Related]
60. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.
Pemmaraju N; Wilson NR; Garcia-Manero G; Sasaki K; Khoury JD; Jain N; Borthakur G; Ravandi F; Daver N; Kadia T; DiNardo C; Jabbour E; Pierce S; Qazilbash M; Konopleva M; Kantarjian H
Blood Adv; 2022 May; 6(10):3027-3035. PubMed ID: 35061885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
